by Mrudula Kulkarni
2 minutes
Merck KGaA Names Michael Klobuchar as EVP of Strategy to Propel Biopharmaceutical Growth
Merck KGaA, a leader in science and technology, has appointed Michael Klobuchar as Executive Vice President of Strategy.
Darmstadt, Germany – June 2024 – Merck KGaA, a leader in science and technology, has appointed Michael Klobuchar as Executive Vice President of Strategy, a role that will commence in June 2024. Klobuchar's new position is part of Merck's strategic initiative to drive growth across its healthcare portfolio, particularly within the biopharmaceutical sector.
Michael Klobuchar brings a robust strategic planning background to his new role, having excelled in similar capacities at other leading pharmaceutical companies. His expertise will be central to enhancing Merck's operations and extending its market reach in the fast-evolving biopharmaceutical landscape.
"Michael's appointment reflects our commitment to advancing Merck’s strategic objectives and strengthening our position in the global healthcare market," stated Belén Garijo, CEO of Merck KGaA. "His deep understanding of the biopharmaceutical industry and proven leadership in strategic innovation will be invaluable as we continue to navigate the complexities of healthcare dynamics and patient needs."
Merck KGaA expects that Klobuchar’s strategic guidance will significantly contribute to the company's ongoing efforts to innovate and improve patient outcomes across its diverse healthcare and pharmaceutical product lines.
For further information about Merck KGaA’s leadership and strategic initiatives, please visit Merck KGaA’s website.
